S. Hibbert

发表

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

N. Greig, T. Foltynie, P. Limousin, 2017, The Lancet.

Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study

V. Libri, T. Foltynie, P. Limousin, 2020, BMJ Open.

Risk of Cardiac Arrhythmias During Hypoglycemia in Patients With Type 2 Diabetes and Cardiovascular Risk

Alan Bernjak, S. Heller, Elaine Chow, 2014, Diabetes.

What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson's Disease: A Post Hoc Analysis.

T. Foltynie, P. Limousin, K. Maclagan, 2018, Journal of Parkinson's disease.

Diagnostic accuracy of magnetic resonance enterography and small bowel ultrasound for the extent and activity of newly diagnosed and relapsed Crohn’s disease (METRIC): a multicentre trial

S. Punwani, C. Mowat, R. Vega, 2019 .

Post hoc analysis of the Exenatide‐PD trial—Factors that predict response

T. Foltynie, P. Limousin, K. Maclagan, 2018, The European journal of neuroscience.

Observer agreement for small bowel ultrasound in Crohn’s disease: results from the METRIC trial

C. Mowat, R. Vega, S. Halligan, 2020, Abdominal Radiology.

Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study

V. Libri, T. Foltynie, P. Limousin, 2021, BMJ Open.

Diagnostic accuracy of magnetic resonance enterography and small bowel ultrasound for the extent and activity of newly diagnosed and relapsed Crohn's disease (METRIC): a multicentre trial

S. Punwani, C. Mowat, R. Vega, 2018, The Lancet Gastroenterology and Hepatology.